Another interesting study found that pre-conditioning tumours with bevacizumab—a vascular endothelial growth factor (VEGF) inhibitor—and then withdrawing treatment, rendered endothelial cells susceptible to reovirus infection, induced vascular collapse and promoted immune-mediated tumour clearance [164]. The gene discussed is VEGFA; the disease is neoplasm.